Effects of Low-Dose Spironolactone Combined with Metformin or Either Drug Alone on Insulin Resistance in Patients with Polycystic Ovary Syndrome: A Pilot Study
Table 1
Baseline characteristics of the participants.
MET group (n = 54)
SPI group (n = 53)
COM (n = 51)
P
Age (years)
27.0 ± 3.7
27.6 ± 3.7
27.2 ± 3.6
>0.05
Number of menstruation per year (normal ≥8/year)
5.7 ± 2.1
6.1 ± 1.9
5.8 ± 1.8
>0.05
SBP (mm Hg)
112 ± 11
124 ± 13
117 ± 9
>0.05
DBP (mm Hg)
72 ± 13
79 ± 10
76 ± 8
>0.05
Weight (kg)
63.2 ± 12.4
65.5 ± 16.8
56.5 ± 9.0
<0.05
BMI (kg/m2)
25.6 ± 4.5
25.9 ± 6.7
25.4 ± 3.7
>0.05
WHR
0.87 ± 0.07
0.87 ± 0.09
0.86 ± 0.09
>0.05
LH/FSH
1.67 ± 0.95
1.86 ± 0.90
2.06 ± 0.99
>0.05
TC (mmol/L)
4.81 ± 1.01
4.91 ± 1.40
4.74 ± 0.98
>0.05
TT (nmol/L)
2.25 ± 1.25
2.09 ± 0.80
2.50 ± 1.03
>0.05
FAI
6.71 ± 8.87
6.99 ± 5.26
7.07 ± 4.21
>0.05
QUICKI
0.33 ± 0.03
0.34 ± 0.03
0.34 ± 0.03
>0.05
HOMA-IR
3.30 ± 2.34
3.02 ± 1.90
2.47 ± 1.63
>0.05
HOMA-β
224.6 ± 166.8
299.6 ± 381
179.9 ± 99
>0.05
FPG (mmol/L)
4.94 ± 0.63
4.79 ± 0.55
4.84 ± 0.61
>0.05
FINS (mU/L)
14.95 ± 9.61
13.87 ± 8.08
11.24 ± 7.1
>0.05
mF-G score
4.2 ± 2.1
4.2 ± 1.3
4.1 ± 1.4
>0.05
AUCins
289.6 ± 151
282.5 ± 146.4
267.8 ± 126
>0.05
AUCglu
22.8 ± 5.4
21.0 ± 4.8
20.5 ± 5.0
>0.05
Rosenfield score
0.89 ± 1.01
0.90 ± 0.92
0.85 ± 1.05
>0.05
SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; WHR: waist-hip ratio; LH/FSH: luteinizing hormone/follicular-stimulating hormone; TC: total cholesterol; TT: total testosterone; FAI: free androgen index; QUICKI: quantitative insulin sensitivity check index; HOMA: homeostatic model assessment; IR: insulin resistance; FPG: fasting plasma glucose; FINS: fasting insulin; mG-G score: modified Ferriman–Gallwey score; AUCglu: oral glucose tolerance test area under curve-glucose; AUCins: oral glucose tolerance test area under curve-insulin.
